✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

GHRP-2 vs GHRP-6: Selectivity vs Orexigenic Activity Compared

GHRP-2 and GHRP-6 are the two most-researched older-generation growth-hormone-releasing peptides. Both bind GHS-R1a (the ghrelin receptor) on pituitary somatotrophs, producing a GH pulse. The structural differences between the two molecules are small but produce a meaningful difference in side-activity profile — specifically in the appetite-stimulation arm. This guide covers the differentiator that matters for research-protocol design.

Mechanism: same receptor, different residue substitutions

Both molecules are hexapeptides built around the same core motif. GHRP-2 = D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2. GHRP-6 = His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. The single substitution at the N-terminus (D-Ala / D-2-Nal in GHRP-2 vs His / D-Trp in GHRP-6) shifts the GHS-R1a binding profile slightly but the more notable effect is on secondary receptor activity.

GHRP-6’s structural similarity to native ghrelin extends to ghrelin’s natural orexigenic effect — the N-terminal residues drive substantial appetite stimulation via the same hypothalamic neurocircuits ghrelin activates in feeding behaviour. GHRP-2’s substitutions attenuate this arm; the molecule is approximately 4-5x less orexigenic than GHRP-6 at matched GH-pulse doses in published research.

Both molecules retain measurable cortisol and prolactin axis activity — the structural elements responsible for HPA-axis activation are conserved in the GHRP class. This is the class-level limitation that Ipamorelin’s selectivity addresses.

Comparison table

Which to pick (research-protocol logic)

• Appetite-stimulation / feeding-behaviour research: GHRP-6. The substantial orexigenic arm is the defining feature.
• Cachexia / undernutrition research models: GHRP-6 for dual GH + appetite stimulation.
• Pure GH-pulse research with minimum appetite confounding: GHRP-2 (less orexigenic than -6) or Ipamorelin (cleanest selectivity).
• Legacy / older-generation GHRP comparator research: Either GHRP-2 or GHRP-6 paired with Ipamorelin or modern GHRPs to characterise selectivity differences.
• Synergistic stack research (with GHRH analogue): Generally Ipamorelin is preferred; GHRP-2/6 are alternative options where the older-class profile is acceptable.

FAQ

Is GHRP-2 actually selective compared with GHRP-6?

Only in the orexigenic dimension. GHRP-2 is approximately 4-5x less orexigenic than GHRP-6 at matched GH-pulse doses. In the cortisol and prolactin dimensions, both are similar to each other and both produce measurable elevations — this is the class-level GHRP limitation. For full selectivity (no orexigenic, no cortisol, no prolactin), Ipamorelin is the correct choice.

Should I just use Ipamorelin instead?

For most research designs, yes — Ipamorelin is the selectivity-optimised modern GHRP and has become the default in published research over the past decade. GHRP-2 and GHRP-6 remain useful as comparator compounds in selectivity-characterisation research, in cachexia / appetite-stimulation models specifically, and in legacy-protocol replication research.

What’s the typical dose pattern?

Published research uses 100-300 mcg per administration, subcutaneous, often pre-sleep to align with the endogenous GH pulse, sometimes thrice daily for maximum pulse-stimulation. Both molecules have similar half-life (~30 min) so dosing patterns are interchangeable from a pharmacokinetic standpoint.

Can GHRP-6 be used for appetite-stimulation research specifically?

Yes — this is its primary remaining research niche. Cachexia models, undernutrition models, and feeding-behaviour neuroscience research use GHRP-6 specifically because the orexigenic arm is the endpoint rather than a confound.

Do GHRP-2 and -6 stack with GHRH analogues?

Yes — the synergistic GHRH + GHRP mechanism applies to all GHRPs binding GHS-R1a. Pairing GHRP-2 or -6 with CJC-1295 without DAC produces the same synergistic GH pulse amplification documented with the Ipamorelin + CJC-1295 reference stack. Most published research uses the Ipamorelin + CJC stack; GHRP-2/6 + CJC stacks are an older convention.

What’s the storage protocol?

Lyophilized vials at -20 °C long-term or 2-8 °C as working stock; reconstituted with bacteriostatic water; reconstituted solution at 2-8 °C with use within ~30 days; protect from light; never freeze-thaw.

Bottom line

GHRP-2 and GHRP-6 are older-generation hexapeptide ghrelin mimetics that share the same primary receptor (GHS-R1a) and similar GH-pulse pharmacology, but differ meaningfully in the orexigenic arm — GHRP-6 has substantially more appetite-stimulation activity. For appetite-stimulation or feeding-behaviour research, GHRP-6 is the right choice; for cleaner GH-pulse research without the appetite confound, GHRP-2 is preferred over GHRP-6 but Ipamorelin is preferred over both. See the Best GH peptides hub for full cluster context.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.